Free Trial

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences logo
$77.82 -0.22 (-0.28%)
As of 05/20/2025 03:58 PM Eastern

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
12
Buy
11

Based on 24 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 1 has given a sell rating, 12 have given a hold rating, and 11 have given a buy rating for EW.

Consensus Price Target

$79.60
2.29% Upside
According to the 24 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $79.60. The highest price target for EW is $90.00, while the lowest price target for EW is $60.00. The average price target represents a forecasted upside of 2.29% from the current price of $77.82.
Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

Sign Up

EW Analyst Ratings Over Time

TypeCurrent Forecast
5/21/24 to 5/21/25
1 Month Ago
4/21/24 to 4/21/25
3 Months Ago
2/21/24 to 2/20/25
1 Year Ago
5/22/23 to 5/21/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
12 Hold rating(s)
13 Hold rating(s)
13 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$79.60$78.55$79.95$93.88
Forecasted Upside2.29% Upside13.46% Upside7.02% Upside3.91% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Edwards Lifesciences Stock vs. The Competition

TypeEdwards LifesciencesMedical CompaniesS&P 500
Consensus Rating Score
2.42
2.81
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside2.29% Upside4,843.17% Upside13.03% Upside
News Sentiment Rating
Positive News

See Recent EW News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2025Piper Sandler
2 of 5 stars
A. Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$80.00 ➝ $83.00+10.95%
4/25/2025Canaccord Genuity Group
2 of 5 stars
William Plovanic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$71.00 ➝ $75.00-0.20%
4/24/2025Robert W. Baird
2 of 5 stars
David Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$72.00 ➝ $75.00+6.64%
4/11/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$78.00 ➝ $75.00+9.87%
2/13/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$88.00 ➝ $90.00+18.84%
2/12/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
2/12/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$85.00 ➝ $85.00+12.99%
2/12/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetIn-Line ➝ In-Line$75.00 ➝ $73.00+2.89%
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Wood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$70.00 ➝ $75.00+5.71%
1/30/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$75.00 ➝ $90.00+26.39%
12/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$82.00 ➝ $90.00+20.97%
12/11/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$81.00 ➝ $83.00+13.00%
12/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$81.00 ➝ $90.00+24.05%
10/30/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/28/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
10/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$72.00 ➝ $78.00+13.04%
9/18/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$85.00 ➝ $70.00+4.14%
9/12/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00+34.71%
9/10/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$90.00 ➝ $75.00+12.66%
9/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$90.00 ➝ $80.00+19.47%
7/31/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
7/25/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/25/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Jennings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$100.00 ➝ $70.00+14.27%
7/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$103.00 ➝ $85.00+34.60%
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$95.00 ➝ $105.00+14.78%
3/26/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMixed ➝ Positive
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
10/16/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$75.00+4.90%
6/27/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:07 AM ET.


Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 16, 2025. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • The current stock price is around $76.79, which reflects a stable trading performance in recent times.
  • Analysts have assigned an average price target of approximately $79.60, indicating potential upside from the current price.
  • Recent upgrades from analysts, including a shift from a "hold" to a "buy" rating, suggest growing confidence in the company's future performance.
  • Edwards Lifesciences Co. has a strong market capitalization of about $44.28 billion, indicating a solid position in the medical research sector.
  • The company maintains a low debt-to-equity ratio of 0.06, suggesting financial stability and lower risk for investors.

Edwards Lifesciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • One analyst has issued a sell recommendation, indicating some skepticism about the stock's future performance.
  • Despite recent upgrades, the majority of analysts still rate the stock as a "hold," suggesting limited immediate growth potential.
  • The company's price-to-earnings ratio of 10.83 may indicate that the stock is fairly valued, limiting potential for significant gains.
  • Recent price target adjustments have shown a downward trend from some analysts, which could signal caution among investors.
  • Market volatility and economic conditions may impact the stock's performance, making it a riskier investment in the current climate.

EW Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $79.60, with a high forecast of $90.00 and a low forecast of $60.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There is currently 1 sell rating, 12 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 2.29% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts.

Edwards Lifesciences has been rated by research analysts at Canaccord Genuity Group, Piper Sandler, Robert W. Baird, and Truist Financial in the past 90 days.

Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating for Edwards Lifesciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EW compares to other companies.


This page (NYSE:EW) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners